drugset
drugset / Trial / NCT00842673

Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease

NCT00842673 ↗

Phase 2 Completed 168 enrolled Sonexa Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 different dose levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo.

Timeline

Start
2009-02
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ISMIDENON Small molecule 30 mg —
Subject ISMIDENON Small molecule 90 mg —
Subject ISMIDENON Small molecule 180 mg —

Indications

Alzheimer disease